

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**维亚生物科技控股集团**  
**VIVA BIOTECH HOLDINGS**

*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **ENTERING INTO THE LETTER OF INTENT IN RELATION TO NEW SHARES SUBSCRIPTION**

The board of directors (the “**Board**”) of Viva Biotech Holdings (the “**Company**”) hereby announces that on June 10, 2023, the Company entered into a letter of intent in relation to subscription of new shares of the Company (the “**Letter of Intent**”) with Ms. Ban Yan (班艷) and Mr. Xiong Wei (熊偉) (collectively, the “**Subscribers**”), pursuant to which, subject to certain conditions, the Subscribers shall irrevocably agree to, within 12 months from the date of execution of the Letter of Intent at the request of the Company, support the Company’s funding need by way of subscribing, at a price of HK\$2.0 per share (the “**Subscription Price**”), for the new ordinary shares to be issued by the Company either in their own names or through enterprise(s) established by them in an aggregate amount of not more than HK\$11.70 million (the “**Subscription**”).

Ms. Ban Yan is chairman of the board of directors of Zhejiang Langhua Pharmaceutical Co., Ltd. (“**Zhejiang Langhua**”), a subsidiary of the Company, and Mr. Xiong Wei is the chief financial officer of Zhejiang Langhua. Calculated based on the aggregate subscription amount of HK\$11.70 million and the subscription price of HK\$2.0 per share, the Subscribers will subscribe, in aggregate, for up to 5,850,000 ordinary shares of the Company (the “**Subscription Shares**”), representing approximately 0.30% of the issued share capital of the Company as enlarged by the issue of the Subscription Shares. The subscription price, being HK\$2.0 per share, represents a premium of approximately 5.26% over the closing price per share of HK\$1.90 as quoted on The Stock Exchange of Hong Kong Limited as of the date immediately prior to the date of the Letter of Intent.

The Subscribers acknowledged and agreed that the Subscription shall only be conducted with the subscription price of HK\$2.0 per share on the following conditions at the Company’s request:

- (1) the Subscribers continue to serve as a director and/or senior management of the Company and/or its subsidiary, namely Zhejiang Langhua, before the completion of the Subscription;
- (2) the Company and/or its subsidiaries have completed financing of more than US\$200 million within 12 months after the date of the Letter of Intent;
- (3) the Subscribers have completed relevant foreign exchange registration, foreign investment approval or filing procedures; and

- (4) the Subscription is conducted in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and other applicable laws, regulations, normative documents and the rules and regulations of the listing place of the Company stipulated by local regulatory authorities.

If the Subscription is materialized, the Company will enter into formal share subscription agreement(s) with the Subscribers in relation to the Subscription. As Ms. Ban Yan, one of the Subscribers, is a director of a subsidiary of the Company, Ms. Ban Yan hence constitutes a connected person of the Company under the Listing Rules). Therefore, if the Subscription is materialized, the Subscription Shares will be issued at the Subscription Price pursuant to a specific mandate to be sought from the independent shareholders at the general meeting of the Company, and the Subscription will constitute a connected transaction of the Company, which is subject to the reporting, announcement, circular and shareholders’ approval requirements under Chapter 14A of the Listing Rules. Further announcement(s) will be made by the Company in compliance with the requirements of the Listing Rules.

By Order of the Board  
**VIVA BIOTECH HOLDINGS**  
**MAO Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, June 11, 2023

*As of the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*